Autolus Therapeutics plc
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies
Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T 90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL...
INNATE PHARMA
Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data Innate...
INNATE PHARMA
Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019
MARSEILLE, France, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) shared new, long-term data from the pivotal...
Karyopharm Therapeutics Inc.
Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting
-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with...
Agios Pharmaceuticals, Inc.
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients – – Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with...
TG Therapeutics, Inc.
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
100% overall response rate (ORR) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13) 100% of patients (n=9) achieved undetectable MRD in...
Pomerantz LLP
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brooks Automation, Inc. - BRKS
NEW YORK, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Brooks Automation, Inc. (“Brooks” or the “Company”) (NASDAQ: BRKS). Such investors are...
ZIOPHARM Oncology Inc
Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting
– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON, Dec. ...
Pomerantz LLP
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Yunji Inc. - YJ
NEW YORK, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Yunji Inc. (“Yunji” or the “Company”) (NASDAQ: YJ). Such investors are advised to...
Pomerantz LLP
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Resideo Technologies, Inc. - REZI
NEW YORK, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Resideo Technologies, Inc. (“Resideo” or the “Company”) (NYSE: REZI). Such investors are...